The effect of microbial ecosystem therapeutic (MET-2) on recurrent Clostridioides difficile infection: a phase 1, open-label, single-group trial
Restoring Equilibrium,
Restoring Health
NuBiyota is a microbiome therapeutics company focused on the development of novel microbiota-based drugs to restore crucial gut equilibrium. An imbalance in this crucial ecosystem is associated with infections, chronic disease and even neurological dysfunction.
NuBiyota is developing a new class of microbiome therapeutics, with multi-strain microbiota candidates for effective microbiota diversity restoration to suppress flares or promote remission in numerous indications.
